Core Viewpoint - The company, Shida Shenghua (603026.SH), announced multiple updates including personnel changes, a profit warning for the first half of 2025, and an extension of the validity period for its A-share issuance plan to specific investors [1][2][6]. Group 1: A-Share Issuance Plan - The board of directors approved a 12-month extension for the validity period of the 2022 A-share issuance plan, which requires shareholder approval [2][4]. - The initial plan aimed to raise up to 4.5 billion yuan for seven projects, including a 500,000-ton electrolyte production facility [4][5]. - The plan faced multiple delays and revisions, with the fundraising amount reduced to 1.99 billion yuan and the cancellation of the electrolyte projects due to feasibility concerns [5]. Group 2: Financial Performance - The company expects a net loss of 52 million to 60 million yuan for the first half of 2025, a significant decrease compared to the previous year [6]. - Revenue and net profit have declined for three consecutive years, with revenues of 8.316 billion yuan, 5.635 billion yuan, and 5.547 billion yuan from 2022 to 2024, reflecting year-on-year changes of -17.86%, -32.24%, and -1.56% respectively [10]. - The main business areas include electrolytes, carbonates, and methyl tert-butyl ether, all of which are currently facing challenges such as overcapacity and declining prices [10]. Group 3: Strategic Partnerships - The company has established a strategic cooperation agreement with CATL, a leading lithium-ion battery manufacturer, to supply an estimated 100,000 tons of electrolyte by December 31, 2025 [10][11]. - This partnership is expected to positively impact the company's operational performance and enhance its market position in the lithium battery materials sector [11].

Core Viewpoint - The company Shida Shenghua is facing significant financial pressure in the first half of 2025, with expected net losses due to product price fluctuations and high costs associated with new facilities [1][2]. Financial Performance - Shida Shenghua anticipates a net profit loss of between 52 million to 60 million yuan for the first half of 2025, a decrease of 90.06 million to 98.06 million yuan compared to the same period last year, representing a year-on-year decline of 236.64% to 257.66% [1]. - The company also expects a loss in its net profit excluding non-recurring items of 53 million to 61 million yuan, down by 84.37 million to 92.37 million yuan from the previous year, reflecting a decline of 268.93% to 294.43% [1]. - This marks the third consecutive year of declining net profit and net profit excluding non-recurring items since 2022 [2]. Revenue Trends - Shida Shenghua's revenue figures for the years 2022 to 2024 were 8.316 billion yuan, 5.635 billion yuan, and 5.547 billion yuan, with year-on-year changes of 17.86%, -32.24%, and -1.56% respectively [2]. - The net profit for the same years was 891 million yuan, 18.726 million yuan, and 16.4196 million yuan, showing declines of 24.42%, 97.9%, and 12.32% respectively [2]. - The net profit excluding non-recurring items was 857 million yuan, 13.2343 million yuan, and 5.3878 million yuan, with declines of 26.4%, 98.46%, and 59.29% respectively [2]. Business Operations - The company has transitioned from traditional chemical operations to focus on new energy and new materials, including sectors such as electrolyte, carbonate, and methyl tert-butyl ether [2]. - The production at the Wuhan base for electrolyte is currently in the customer introduction phase, leading to underproduction and high fixed costs [3]. - The decline in profits is also attributed to falling prices of methyl tert-butyl ether products and lithium fluoride raw materials [3]. Regulatory Issues - Shida Shenghua received an administrative regulatory decision due to issues in insider information management, leading to corrective measures and warnings issued to key executives [4].

站在当前时点展望下半年，锂电行业周期底部虽已探明，但以电解液为代表的产业链环节的需求具有不 确定性，并且供给出清漫长，或导致材料制造商下半年仍面临经营压力。 净利润预亏5200万元到6000万元，今年上半年，昔日锂电"明星股"石大胜华（603026.SH）仍未摆脱亏 损的困境。 站在当前时点展望下半年，锂电行业处于缺乏积极信号的空窗期。周期底部虽已探明，但以电解液为代 表的产业链环节的需求具有不确定性，并且供给出清漫长，可能会导致材料制造商下半年仍面临经营压 力。 截至7月2日收盘，石大胜华报收36.78元，总市值75亿元，相较历史最高价345.95元（前复权），已累计 回撤92.52%。 产品跌价致使二季度续亏 石大胜华二季度的亏损，可能出现了加剧的情况。 披露数据显示，今年一季度，石大胜华净利润亏损2853.89万元，按照上半年预亏上限计算，该公司二 季度亏损约3146万元。 石大胜华解释，上半年净利润预亏，主要有三方面因素：第一、武汉基地电解液装置产品正处于客户导 入阶段，产量未达产，固定费用偏高；第二、当期甲基叔丁基醚系列产品因产品价格下降导致利润降 低；第三，二季度氟化锂和氟化锂的原材料碳酸锂产品价 ...

ST智知：副总裁王东辞职 7月2日，ST智知（603869）发布公告称，公司副总裁王东因个人原因申请辞去公司副总裁职务及其在 公司控股子公司的一切任职，辞职后不再担任公司任何职务。王东的辞职报告自送达公司董事会之日起 生效。 资料显示，ST智知成立于1986年5月，是以数智技术保障城市安全和提升产业智能能力的运营商。 所属行业：计算机–IT服务Ⅱ–IT服务Ⅲ 皓元医药：拟以债转股方式对全资子公司增资4亿元 7月2日，皓元医药（688131）发布公告称，公司将以债转股方式向全资子公司安徽皓元药业有限公司增 资4亿元。本次增资完成后，安徽皓元的注册资本将由4亿元增加至8亿元。 石大胜华：上半年预亏5200万元至6000万元 7月2日，石大胜华（603026）发布2025年半年度业绩预告，预计2025年半年度实现归属于上市公司股东 的净亏损5200万-6000万元，同比减少236.64%到257.66%；预计实现归属于上市公司股东的扣除非经常 性损益的净利润5300万-6100万元，同比减少268.93%到294.43%。 资料显示，石大胜华成立于2002年12月，主营业务是新能源材料领域，公司新能源、新材料业务技 ...

Core Viewpoint - The A-share companies have accelerated the disclosure of mid-term performance forecasts, with 8 companies announcing their forecasts this week, indicating a positive trend in profitability for most companies [1][4]. Group 1: Company Performance Forecasts - Among the 8 companies that disclosed their mid-term forecasts, 7 expect to report profits while 1 anticipates a loss [1]. - Han Yu Pharmaceutical is projected to achieve a net profit of 142 million to 162 million yuan, representing a year-on-year growth of 1470.82% to 1663.89%, the highest growth rate among the companies [1][3]. - Xinhecheng forecasts a net profit of 330 million to 375 million yuan, with a year-on-year increase of 50% to 70% [2][3]. - Guomai Technology expects a net profit of 12.5 million to 15.6 million yuan, with a year-on-year growth of 60.52% to 100.33% [2]. - Weichai Heavy Machine anticipates a net profit of 13.18 million to 15.06 million yuan, with a year-on-year increase of 40% to 60% [2]. - The only company forecasting a loss is Shida Shenghua, expecting a loss of 52 million to 60 million yuan, a decline of 236.64% to 257.66% year-on-year [2][3]. Group 2: Industry Insights - Han Yu Pharmaceutical's revenue is primarily driven by international business, benefiting from global market demand, approval of its product by the FDA, and effective cost control [3]. - Xinhecheng, a leader in the vitamin industry, reported growth in sales volume and prices of its main products in the nutrition segment, contributing to its improved performance [3]. - The overall trend in the A-share market shows that out of 29 companies that have released mid-term forecasts, 27 expect profits and 2 anticipate losses, with 23 companies projecting year-on-year profit growth [4].

证券代码：603026 证券简称：石大胜华 公告编号：临 2025-024 石大胜华新材料集团股份有限公司 关于注销 2022 年股票期权激励计划 部分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 本次股票期权拟注销数量：202.88 万股 石大胜华新材料集团股份有限公司（以下简称"公司"）于 2025 年 7 月 1 日召开了第八届董事会第十六次会议和第八届监事会第九次会议审议通过了《关 于注销 2022 年股票期权激励计划部分股票期权的议案》，同意对 2022 年股票期 权激励计划已离职激励对象和第三个行权期公司业绩考核未达标导致不符合行 权条件对应的股票期权合计 202.88 万份股票期权进行注销。现将相关事项公告 如下： 一、2022 年股票期权激励计划的基本情况 届监事会第八次会议，审议通过了《关于石大胜华 2022 年股票期权激励计划（草 案）及摘要的议案》《关于石大胜华 2022 年股票期权激励计划实施考核管理办 法的议案》《关于石大胜华 2022 年股票期权激励计划激 ...

证券代码：603026 证券简称：石大胜华 公告编号：临 2025-027 石大胜华新材料集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 （二）业绩预告情况 利润-5,200.00 万元到-6,000.00 万元，与上年同期（法定披露数据）相比，将 减少 9,005.72 万元到 9,805.72 万元，同比减少 236.64%到 257.66%。 -6,100.00 万元，与上年同期（法定披露数据）相比，将减少 8,437.40 万元到 （三）本次所预计的业绩未经注册会计师审计。 二、上年同期业绩情况 （一）归属于上市公司股东的净利润：3,805.72 万元。归属于上市公司股 东的扣除非经常性损益的净利润 3,137.40 万元。 （二）每股收益：0.19 元。 三、本期业绩预减的主要原因 本报告期归属于上市公司股东的净利润较上年同期减少的原因： 偏高。 四、风险提示 五、其他说明事项 以上预告数据仅为初步测算数据，具体准确的财务数据以公司正式 ...

关于延长 2022 年度向特定对象发行 A 股股票股东大会 决议有效期及授权有效期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司于 2022 年 8 月 1 日召开 2022 年第五次临时股东大会，审议并通过了 《关于公司 2022 年非公开发行 A 股股票方案的议案》及相关议案。根据 2022 年第五次临时股东大会对董事会的授权，公司于 2023 年 2 月 15 日召开第七届董 事会第三十二次会议审议并通过了《关于修订公司 2022 年度非公开发行 A 股股 票预案的议案》。根据上述决议，公司本次发行的股东大会决议有效期为自 2022 年第五次临时股东大会审议通过之日起 12 个月。 公司于 2023 年 3 月 7 日召开 2023 年第三次临时股东大会，审议通过了《关 于提请股东大会授权董事会办理本次向特定对象发行股票相关事宜的议案》等相 关议案。根据股东大会决议，公司股东大会授权公司董事会并由董事会授权董事 长及其授权人士全权办理向特定对象发行股票的有关事宜的有效期为自 2023 年 第三次临时股 ...

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

证券代码：603026 证券简称：石大胜华 公告编号：临 2025-024 石大胜华新材料集团股份有限公司 关于注销 2022 年股票期权激励计划 部分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、 2022 年 5 月 3 日，公司分别召开了第七届董事会第十七次会议和第七 届监事会第八次会议，审议通过了《关于石大胜华 2022 年股票期权激励计划（草 案）及摘要的议案》《关于石大胜华 2022 年股票期权激励计划实施考核管理办 法的议案》《关于石大胜华 2022 年股票期权激励计划激励对象名单的议案》。 详情见 2022 年 5 月 5 日公司在上海证券交易所网站（www.sse.com.cn）披露 的相关公告。 2、2022 年 5 月 6 日至 2022 年 5 月 15 日，公司通过公司内部网站对 激励对象姓名和职务进行了内部公示，公示期共 10 天，在公示期限内，公司监 事会未接到任何人对公司激励对象提出的异议。公司于 2022 年 5 月 20 日在 上海证券交易所网站（ ...